Limited clinical role of blood eosinophil levels in early life atopic disease: A mother–child cohort study

Abstract

AbstractBackgroundBlood eosinophil count is a well‐established biomarker of atopic diseases in older children and adults. However, its predictive role for atopic diseases in preschool children is not well established.ObjectiveTo investigate the association between blood eosinophil count in children and development of atopic diseases up to age 6 years.MethodsWe investigated blood eosinophil count at age 18 months and 6 years in relation to recurrent wheeze/asthma, atopic dermatitis, allergic rhinitis, and allergic sensitization during the first 6 years of life in the two Copenhagen Prospective Studies on Asthma in Childhood cohorts (n = 1111). Blood eosinophil count was investigated in association with remission of existing atopic disease, current atopic disease, and later development of atopic disease.ResultsBlood eosinophil count at 18 months was not associated with current wheezing/asthma or atopic dermatitis, while blood eosinophil count at age 6 years was associated with increased occurrence of current wheezing/asthma (OR = 1.1; 1.04–1.16, p = .0005), atopic dermatitis (OR = 1.06; 1.01–1.1, p = .02), and allergic rhinitis (OR = 1.11; 1.05–1.18, p = .0002). Blood eosinophil count at 18 months did not predict persistence or development of recurrent wheeze/asthma or atopic dermatitis at age 6 years.ConclusionBlood eosinophil count at 18 months was not associated with current wheezing/asthma or atopic dermatitis and did not predict persistence or development of disease. This implies a limited clinical role of blood eosinophil levels in early‐life atopic disease and questions the clinical value of blood eosinophil counts measured in toddlers as a predictive biomarker for subsequent atopic disease in early childhood.